- Previous Rank-
- Revenue 3 Yr Annual Growth Rate18%
- Revenue 3 Yr Growth Rank88
- EPS 3 Yr Annual Growth Rate83%
- EPS 3 Yr Growth Rank12
- Total Return 3 Yr Annual Rate2%
- Total Return 3 Yr Rank92
Jazz, which became an Irish company after its merger with Azur Pharma in 2012, has a drug portfolio focused on narcolepsy and hematology.
Company Information
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
| Location | Dublin, Ireland |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | 1 |
| Years on List | 2 |
| CEO | Bruce Cozadd |
| Website | http://www.jazzpharma.com |
Looking for leads, investment insights, or competitive intelligence?Purchase Now
Revenue, Net Income
| Revenue past four quarters ($M) | $1,528 |
| Net Income past four quarters ($M) | $408 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 88 |
| Revenue 3 Yr Annual Growth Rate | 18% |
| EPS 3 Yr Growth Rank | 12 |
| EPS 3 Yr Annual Growth Rate | 83% |
| Total Return 3 Yr Rank | 92 |
| Total Return 3 Yr Annual Rate | 2% |
| Beat S&P 500 (9.6%) | no |
| P/E Ratio | 21 |